Silverarc Capital Management »

Zura Bio shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Zura Bio (ZURA) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Zura Bio

Tip: Access up to 7 years of quarterly data

All positions including Zura Bio held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zura Bio by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $2.7M 404k 6.60
2023-06-30 $1.3M 160k 8.20

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Zura Bio

Dr. Jeffrey R. Jay, M.D.
Citadel Advisors
Vanguard Group
Charles Schwab Investment Management
Raymond James & Associates
Hudson Bay Capital Management
Bank of New York Mellon
Two Sigma Investments
Bank of America Corporation
Alliancebernstein
Barclays
Occudo Quantitative Strategies
Goldman Sachs Group
Rhumbline Advisers
Jpmorgan Chase & Co

View all funds holding Zura Bio